Recombinant Human BST-2/Tetherin Protein, CF Summary
Product Specifications
Asn49-Ser161, with an N-terminal Met and C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9939-BS
Formulation | Lyophilized from a 0.2 μm filtered solution in MES and NaCl with Trehalose. |
Reconstitution | Reconstitute at 250 μg/mL in water. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
When Recombinant Human BST-2/Tetherin (Catalog # 9939-BS) is immobilized at 1 µg/mL (100 µL/well), Recombinant Viral Dengue Virus 4 Envelope Fc Chimera binds with an ED50 of 0.2-1.6 μg/mL.
2 μg/lane of Recombinant Human BST-2/Tetherin (Catalog # 9939-BS) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing bands at 13 kDa and 31 kDa.
Reconstitution Calculator
Background: BST-2/Tetherin
BST-2, also known as tetherin or CD317, is a type II transmembrane protein that is constitutively expressed in several cell types including T cells, B cells, monocytes and macrophages, as well as on several cancer cell lines including the B cell lineage in multiple myeloma (1, 2). Originally named bone marrow stromal cell antigen 2, BST-2 was identified to inhibit viral replication due to its unusual topology (3-5). The extracellular C-terminus of the protein is modified with GPI (glycosylphosphatidylinositol) membrane anchor, which enables BST-2 to interact at each of its ends with the cell or the viral membrane. The ectodomain of the protein also contains three cysteine residues that can form intermolecular disulfide bonds to form parallel dimers (2). Human BST-2 consists of a 20 amino acid (aa) cytoplasmic domain, a 28 aa transmembrane segment, and a 113 aa extracellular domain (ECD). Within the ECD, human BST-2 shares 41% and 35% aa sequence identity with mouse and rat BST-2, respectively. BST-2 was identified as a major mediator of the innate immune defense against enveloped viruses. BST-2 was shown to interact with formed viral particles tethering them to surface of infected cells, thereby reducing viral release (6). BST-2 inhibits the release of diverse group of enveloped viruses including members of the retrovirus, togavirus, filovirus, arenavirus, flavivirus, rhabdovirus, orthohepadnavirus, orthomyxovirus, poxvirus, paramyxovirus, and herpesvirus families (7-9). The mechanism BST-2 inhibition of viral budding was suggested to be through directly bridging the host and viral membranes through simultaneous embedding of its two opposing membrane anchors (9). To counteract BST-2 functions, many viruses have evolved to develop strategies to antagonize BST-2 function (9, 10). In addition to inhibiting viral release, BST-2 can act as an innate immune sensor of viral infections by acting as a pattern recognition receptor that activates NF-kappa B to induce inflammatory responses through interactions with the immunoglobulin-like transcript 7 (ILT7/LILRA4) (10, 11).
- Evans, D.T. et al. (2010) Trens Microbiol. 18:388.
- Ohtomo, T. et al. (1999) Biochem. Biophys. Res. Commun. 258:583.
- Ishikawa, J. et al. (1995) Genomics. 26:527.
- Neil, S.J. et al. (2008) Nature. 451:425.
- Kupzig, S. et al. (2003) Traffic. 4:694.
- Janvier K. et al. (2012) Curr HIV Res. 10:315.
- Evans D.T. et al. (2010) Trends Microbiol. 18:388.
- Mahauad-Fernandez W.D. et al. (2012) Immun Inflamm Dis. 4:4.
- Swiecki M. et al. (2013) Mol Immunol. 54:132.
- Sauter D. (2014) Front Microbiol. 5:163.
- Hotter D. et al. (2013) J Mol Biol. 425:4956.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human BST-2/Tetherin Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human BST-2/Tetherin Protein, CF and earn rewards!
Have you used Recombinant Human BST-2/Tetherin Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image